The U.S. implantable medical device market is forecasted to grow more than 8% per year and is on pace to exceed $50 billion in 2015. Growth in this sector is anticipated to remain strong despite continuing product recalls and safety controversies, particularly in the cardiac implant segment. Next-generation devices centered around new technologies and improved materials will help propel market growth. New technologies will also lessen the thrombosis risk of drug-eluting coronary stents.
This special report focuses on the market leaders for implants as well as the products in development anticipated to head this area in the years to come. This compilation’s prescription-product pipeline details the following information for each medicine: chemical or substance composition, intended indication, class of drug, clinical status, region of development, and the product developer/intended marketer. Pipeline status details preclinical development, Phase I, Phase I/II, Phase II, Phase II/III, Phase III, and awaiting approval. Regions of development include the United States, Europe, and Japan. A directory of implant prescription-drug developers and marketers is included.
Additionally provided in this report is a listing of implant medical-device entries, sorted by device class, as well as a directory of medical-device companies associated with the implant field.